BriaCell Therapeutics (TSE:BCT) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BriaCell Therapeutics has announced that the FDA has authorized an Expanded Access Policy allowing metastatic breast cancer patients to receive their novel Bria-IMT™ immunotherapy outside of the current Phase 3 clinical trial. This policy aims to provide additional treatment options for patients who have exhausted other therapies, with the hope of improving care for a disease that remains a leading cause of cancer death among American women.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.